Rhythm Pharmaceuticals, Inc.   Report issue

Contributed to NME For profit Phase 2 Phase 4
Founded: Boston MA United States (2008)

Organization Overview

First Clinical Trial
2012
NCT02431442
First Marketed Drug
2020
setmelanotide (Imcivree)
First NDA Approval
2020
setmelanotide (Imcivree)
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

RHYTHM | Rhythm Pharmaceuticals, Inc. | RHYTHM PHARMACEUTICALS INC | Rhythm Pharmceuticals, Inc | Rhythm Pharmceuticals, Inc.

Active Ingredients

Marketed Drugs (1)

setmelanotide (Imcivree) (2020 NDA)

Drugs in Phase 4 Trials (2)

moxifloxacin (avelox) (1 trial)

setmelanotide (Imcivree) (20 trials)

Drugs in Phase 2 Trials (1)

relamorelin (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alstrom Syndrome (Phase 3)

Bardet-Biedl Syndrome (Phase 3)

Constipation (Phase 2)

Diabetes Complications (Phase 2)

Diabetes Mellitus (Phase 2)

Gastroparesis (Phase 2)

Genetic Diseases, Inborn (Phase 3)

Laurence-Moon Syndrome (Phase 3)

Obesity (Phase 3)

Obesity, Morbid (Phase 3)

Overweight (Phase 2)

Prader-Willi Syndrome (Phase 2)

Renal Insufficiency (Phase 1)

Smith-Magenis Syndrome (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 22
  • # of Trial APIs: 3